245 related articles for article (PubMed ID: 30267383)
1. MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133
Yang L; Li N; Yan Z; Li C; Zhao Z
J Mol Neurosci; 2018 Nov; 66(3):369-377. PubMed ID: 30267383
[TBL] [Abstract][Full Text] [Related]
2. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
3. Down-expression of miR-154 suppresses tumourigenesis in CD133(+) glioblastoma stem cells.
Yang L; Yan Z; Wang Y; Ma W; Li C
Cell Biochem Funct; 2016 Aug; 34(6):404-13. PubMed ID: 27338789
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
5. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6.
Xi Z; Wang P; Xue Y; Shang C; Liu X; Ma J; Li Z; Li Z; Bao M; Liu Y
Oncotarget; 2017 Apr; 8(15):24949-24963. PubMed ID: 28212562
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
8. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
9. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
11. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133
Xu Y; Lai Y; Weng H; Tan L; Li Y; Chen G; Luo X; Ye Y
Aging (Albany NY); 2019 May; 11(9):2551-2564. PubMed ID: 31056532
[TBL] [Abstract][Full Text] [Related]
12. MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6.
Yang L; Lin Z; Wang Y; Gao S; Li Q; Li C; Xu W; Chen J; Liu T; Song Z; Liu G
Mol Carcinog; 2018 Mar; 57(3):419-428. PubMed ID: 29144562
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
14. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
16. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
17. Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells.
Shi L; Wan Y; Sun G; Gu X; Qian C; Yan W; Zhang S; Pan T; Wang Z; You Y
Neuromolecular Med; 2012 Dec; 14(4):303-16. PubMed ID: 22711523
[TBL] [Abstract][Full Text] [Related]
18. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
Nakai E; Park K; Yawata T; Chihara T; Kumazawa A; Nakabayashi H; Shimizu K
Cancer Invest; 2009 Nov; 27(9):901-8. PubMed ID: 19832037
[TBL] [Abstract][Full Text] [Related]
19. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.
Jin F; Zhao L; Guo YJ; Zhao WJ; Zhang H; Wang HT; Shao T; Zhang SL; Wei YJ; Feng J; Jiang XB; Zhao HY
Brain Res; 2010 Jun; 1336():103-11. PubMed ID: 20388502
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
